School of Medicine
Showing 221-230 of 747 Results
-
Mary Hawn, MD, FACS
Emile Holman Professor of Surgery
Current Research and Scholarly InterestsMy area of research is health services researcher focusing on surgical quality measurement and policy. I have a background and training in epidemiology coupled with my leadership roles in surgical quality measurement. My expertise and extensive experience in evaluation of surgical quality process and outcome linkage has impacted national policy and changed guidelines. We performed a comprehensive evaluation of the Surgical Care Improvement Project (SCIP) implementation using national VA data. Defining robust metrics of surgical quality that are actionable and can lead to sustained improvement in our field are of utmost importance. I also have experience with risk prediction modeling for surgical patients. Our Decision Support for Safer Surgery study developed models of real-time risk prediction for major complications and prospectively validated our models in patients and with expert surgeons. We were able to discern where computational risk prediction has added value and where it falls short. We currently have a national study investigating readmissions following major surgical procedures to identify opportunities for improving care and reducing costs.
-
Mohammed (Maunie) Hayat
Affiliate, Department Funds
Resident in Rad/Interventional RadiologyBioInterventional & Diagnostic Radiology - Stanford Healthcare - M.D.
-
Melanie Hayden Gephart
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences
BioI am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including gliomas, brain metastases, meningiomas, and schwannomas. I direct the Stanford Brain Tumor Center and the Stanford Brain Metastasis Consortium, collaborative unions of physicians and scientists looking to improve our understanding and treatment of brain tumors. My laboratory seeks greater understanding of the mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We study how rare cancer cell populations survive and migrate in the brain, inadvertently supported by native brain cells. We develop novel cerebrospinal fluid-based biomarkers to track brain cancer treatment response, relapse, and neurotoxicity. Our bedside-to-bench-to-bedside research model builds on a foundation of generously donated patient samples, where we test mechanisms of brain cancer growth, develop novel pre-clinical models that reliably recapitulate the human disease, and facilitate clinical trials of new treatments for patients with brain cancer.
www.GephartLab.com
https://stan.md/BrainMets
@HaydenGephartMD
